As of close of business last night, Humacyte Inc’s stock clocked out at $3.11, down -7.72% from its previous closing price of $3.37. In other words, the price has decreased by -$0.2600 from its previous closing price. On the day, 961715 shares were traded.
Ratios:
To gain a deeper understanding of HUMA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.79 and its Current Ratio is at 6.79. In the meantime, Its Debt-to-Equity ratio is 0.53 whereas as Long-Term Debt/Eq ratio is at 0.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 11, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
On August 14, 2023, Piper Sandler Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $2.75 to $3.50.
On June 22, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.Cantor Fitzgerald initiated its Overweight rating on June 22, 2023, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 14 ’23 when Dougan Brady W sold 2,000,000 shares for $2.78 per share. The transaction valued at 5,560,000 led to the insider holds 6,191,140 shares of the business.
Niklason Laura E sold 2,000,000 shares of HUMA for $5,560,000 on Sep 14 ’23. The President, CEO and Director now owns 6,191,140 shares after completing the transaction at $2.78 per share. On Aug 21 ’23, another insider, Ayabudge LLC, who serves as the 10% Owner of the company, sold 602,443 shares for $3.39 each. As a result, the insider received 2,042,282 and left with 8,191,140 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 393.04M and an Enterprise Value of 349.83M.
Stock Price History:
Over the past 52 weeks, HUMA has reached a high of $5.60, while it has fallen to a 52-week low of $1.96. The 50-Day Moving Average of the stock is 3.3592, while the 200-Day Moving Average is calculated to be 3.1152.
Shares Statistics:
It appears that HUMA traded 802.57K shares on average per day over the past three months and 1.87M shares per day over the past ten days. A total of 103.23M shares are outstanding, with a floating share count of 84.62M. Insiders hold about 27.66% of the company’s shares, while institutions hold 15.21% stake in the company. Shares short for HUMA as of Feb 15, 2024 were 6.56M with a Short Ratio of 8.17, compared to 6.13M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.33% and a Short% of Float of 10.40%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.27, while EPS last year was -$0.04. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.21 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.92 and -$1.1 for the fiscal current year, implying an average EPS of -$1.06. EPS for the following year is -$0.95, with 7 analysts recommending between -$0.86 and -$1.03.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $2.93M in the next fiscal year. The high estimate is $6.1M and the low estimate is $700k. The average revenue growth estimate for next year is up 4,783.30% from the average revenue estimate for this year.
